PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced a new multi-target collaboration and license agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) focused on the discovery and development of novel peptide drug conjugates.